Login / Signup

Efficacy and safety of infliximab: A comparison with other biological disease-modifying anti-rheumatic drugs.

Daisuke KobayashiSatoshi ItoChinatsu TakaiEriko HasegawaYumi NomuraHiroshi OtaniAsami AbeHajime IshikawaAkira MurasawaIchiei NaritaKiyoshi Nakazono
Published in: Modern rheumatology (2017)
Intensification of IFX was effective and well tolerated for MTX resistant patients.
Keyphrases
  • end stage renal disease
  • newly diagnosed
  • ejection fraction
  • chronic kidney disease
  • peritoneal dialysis
  • prognostic factors
  • ulcerative colitis